Literature DB >> 11580151

Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial.

L Alric1, M Duffaut, J Selves, K Sandre, M Mularczyck, J Izopet, H Desmorat, C Bureau, N Chaouche, B Dalbergue, J P Vinel.   

Abstract

BACKGROUND/AIMS: Our aim was to assess whether histological response was improved by continuing interferon-alpha (IFN) treatment in patients with chronic hepatitis C (HCV) with a biochemical response and no viral clearance after a usual IFN treatment.
METHODS: Fifty-seven patients with normal alanine aminotransferase (ALAT) levels and positive HCV RNA at the end of a 1 year IFN treatment were randomly assigned to either group 1 (n = 28) where IFN was stopped, or group 2 (n = 29) where IFN was continued for 1 more year with gradual reduction of the dose to keep serum ALAT activity below the upper limit of normal. Liver biopsies were obtained before, and then 6 months after the end of treatment.
RESULTS: Knodell's index improved between paired biopsies in group 2 (8.2+/-2.4 vs. 5.5+/-2.1), but not in group 1 (8+/-2.3 vs. 6.5+/-2). In post-treatment biopsies, the METAVIR activity score was significantly lower in group 2 than in group 1 (0.7+/-0.2 vs. 1.1+/-0.3, P < 0.05). In group 2, an improvement of the METAVIR fibrosis score was observed (1.3+/-0.4 vs. 1.1+/-0.2), whereas fibrosis progressed in group 1 (1.3+/-0.4 vs. 1.6+/-0.4).
CONCLUSIONS: Maintenance therapy by the minimal dose of IFN able to maintain biochemical response prevents histological progression in the sub-group of patients without virological response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11580151     DOI: 10.1016/s0168-8278(01)00110-6

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  10 in total

1.  Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.

Authors:  Robert J Fontana; Jules L Dienstag; Herbert L Bonkovsky; Richard K Sterling; Deepa Naishadham; Zachary D Goodman; Anna S F Lok; Elizabeth C Wright; Grace L Su
Journal:  Gut       Date:  2010-07-30       Impact factor: 23.059

2.  Cardiac fibroblast transcriptome analyses support a role for interferogenic, profibrotic, and inflammatory genes in anti-SSA/Ro-associated congenital heart block.

Authors:  Robert M Clancy; Androo J Markham; Tanisha Jackson; Sara E Rasmussen; Miroslav Blumenberg; Jill P Buyon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

3.  Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.

Authors:  Robert J Fontana; Arun J Sanyal; Marc G Ghany; William M Lee; Andrea E Reid; Deepa Naishadham; Gregory T Everson; Jeffrey A Kahn; Adrian M Di Bisceglie; Gyongyi Szabo; Timothy R Morgan; James E Everhart
Journal:  Gastroenterology       Date:  2010-03-06       Impact factor: 22.682

Review 4.  Management of untreated and nonresponder patients with chronic hepatitis C.

Authors:  Leonard B Seeff; Marc G Ghany
Journal:  Semin Liver Dis       Date:  2010-10-19       Impact factor: 6.115

Review 5.  Managing chronic hepatitis C in the difficult-to-treat patient.

Authors:  Nyingi Kemmer; Guy W Neff
Journal:  Liver Int       Date:  2007-12       Impact factor: 5.828

6.  Interferon-beta reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects.

Authors:  Junichi Tanabe; Akiko Izawa; Natsumi Takemi; Yasushi Miyauchi; Yuichi Torii; Hiromi Tsuchiyama; Tomohiko Suzuki; Saburo Sone; Kazuki Ando
Journal:  Immunology       Date:  2007-07-20       Impact factor: 7.397

7.  Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis.

Authors:  Yoon Seok Roh; Surim Park; Jong Won Kim; Chae Woong Lim; Ekihiro Seki; Bumseok Kim
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

8.  Sustained eradication of hepatitis C virus by low-dose long-term interferon therapy in a renal transplant recipient with dual infection with hepatitis B and C viruses: a case report.

Authors:  Ming-Ling Chang; Ping-Chin Lai; Chau-Ting Yeh
Journal:  J Med Case Rep       Date:  2011-06-29

Review 9.  Maintenance interferon therapy in chronic hepatitis C patients who failed initial antiviral therapy: A meta-analysis.

Authors:  Hung-Chang Hung; Hsien-Hua Liao; Shiuan-Chih Chen; Shih-Ming Tsao; Yuan-Ti Lee
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 10.  Type I IFN exhaustion is a host defence protecting against secondary bacterial infections.

Authors:  Y Furuya; A Müllbacher
Journal:  Scand J Immunol       Date:  2013-11       Impact factor: 3.487

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.